Fulton Bank’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Fulton Bank’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,802	Closed	-$234K	–	683
2024 Q4	$234K	Buy	+2,802	New	+$230K	0.01%	597

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Fulton Bank's ITCI Position: Q1 2025 in Review

Fulton Bank sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 2,802 shares — an estimated $234K sold.

Fulton Bank first reported a position in ITCI in Q4 2024 and held it in 1 quarter. The position peaked at $234K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Fulton Bank reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Fulton Bank sold 2,802 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $234K.
Fulton Bank first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 1 quarter.
Fulton Bank's Intra-Cellular Therapies Inc. position peaked at $234K in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Fulton Bank's 13F filing for Q1 2025, filed 9 Apr 2025.